OMNICELL, INC. Q3 FY2026 earnings call

• Strong Execution: Delivered results above the high end of guidance, driven by cost efficiency, favorable customer mix, and disciplined spending.
• Omnisphere Platform: The cloud-native platform is connecting with solutions across the medication use journey. Subscription-based pricing is viewed favorably for its predictability. General availability is targeted for H1 2027.
• Titan XT Refresh: First shipments are imminent in H2 2026. The hardware remains foundational, with Omnisphere providing enterprise-wide visibility. Sales are often bundled as an integrated solution.
• Leasing Strategy: Leasing programs are being used to overcome early barriers in competitive deals, accounting for roughly 30% of the marketplace. It allows competition on reliability and innovation rather than just price.
• Customer Success Metrics: Specific examples include a 70% time savings in restock workflows for one community health system and a 41% increase in pharmacist-led clinical interventions for a large regional system.
• Install Base Dynamics: The current XT install base is younger than the previous G-series cycle, affecting near-term pacing. However, the total replacement opportunity exceeds $2.5 billion.
• Operational Discipline: Management is focusing on cross-functional alignment between product strategy, development, and customer success to drive sustained growth and leverage.

Total revenue was $308 million, exceeding the high end of guidance. Product revenue contributed approximately $173 million (56% of total), and service revenue contributed approximately $135 million (44% of total). Non-GAAP EBITDA was $45 million.

• Q4 2026 Revenue: Raised/Lowered? Narrowed range to $295 million - $301 million (previously implied broader uncertainty).
• Q4 2026 Non-GAAP EBITDA: Raised to $30 million - $36 million (previously $32M-$37M full year context, now specific Q4 lift).
• Full Year 2026 Non-GAAP EBITDA: Raised to $187 million - $193 million (previously $187M-$193M range maintained but confidence increased due to Q3 outperformance).
• Full Year 2026 Non-GAAP EPS: Raised to $2.48 - $2.56.
• Product Bookings: Reiterated range of $425 million - $560 million.
• Total Revenue FY26: Narrowed to $1.225 billion - $1.231 billion.
• ARR Guidance: Tightened to $660 million - $670 million.

• Pipeline Timing Variability: Booking timing is back-end weighted and subject to multi-quarter capital approval cycles, making quarterly revenue recognition variable.
• Competitive Binary Nature: Wins/losses in competitive deals are binary; market share gains are not guaranteed despite a growing pipeline.
• Memory Chip Costs: Anticipated ~$6 million margin hit from increased memory component costs in H2 2026.
• 340B Program Impact: Modest negative impact expected on 2026 ARR due to evolving drug pricing program policies.
• Implementation Lag: Competitive deal conversions may take 9-12 months to reach revenue recognition, delaying financial benefits.

Q: How should investors view the variability in 2026 product bookings guidance given the pipeline maturity?

A: Nnamdi explained that conversations are maturing into decision phases, particularly for the XT refresh and competitive opportunities. Baird added that bookings are back-end weighted and influenced by the binary nature of competitive deals and customer-specific capital timelines, making narrow projections difficult despite strong pipeline momentum.

Q: What are the economic implications of leasing cabinets versus purchasing them?

A: Baird noted that leasing opens conversations focused on clinical value rather than price. Economically, lease revenue is recognized upfront like sales, causing slight initial gross margin erosion. However, interest income flows through product revenue over the lease term, improving margins over the lifecycle.

Q: How does Titan XT relate to Omnisphere monetization and the $2.5 billion opportunity?

A: Nnamdi clarified that customers are sold the combined enterprise solution. Baird stated the $2.5 billion figure refers to hardware-only refresh of the installed base. Omnisphere monetization is incremental, tied to attachment rates over a multi-year journey as customers migrate to the cloud-native platform.

Q: Why is there a sequential decline in Q4 product revenue expectations compared to Q3?

A: Baird attributed this to narrowing visibility and the back-end weighting of bookings, which delays revenue recognition. Nnamdi added that Titan XT shipments are just beginning, and competitive deal implementations typically take 9-12 months to convert to revenue, pushing benefits into 2027.

Q: Are lease conversations concentrated among smaller health systems or competitors?

A: Nnamdi indicated that leasing is prevalent among primary competitor customers (~30% of the market). He emphasized that while the XT install base is younger than past cycles, OmniCell remains confident in gaining market share through its superior value proposition and newer hardware offerings.